ImmunoVest

ImmunoVest is a Singapore based biotechnology company focusing on the clinical development and clinical trial of NK cells and Car-T for cancer treatments. The company's business model is centred around developing innovative, cutting-edge therapies that have the potential to revolutionize the treatment of cancer. The company's intellectual property includes patented microcarriers, pluripotency markers, additives, and safety markers. These patents allow for the formation of microcarriers-stem cell complexes in 3D culture, differentiation between undifferentiated and differentiated stem cells, maintenance of cell stability in long-term culture, and the removal of undifferentiated ESC and cancer stem cells.